FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892329410> ?p ?o ?g. }

• W2892329410 endingPage "271" @default.
• W2892329410 startingPage "260" @default.
• W2892329410 abstract "Dopamine (DA)-replacement therapy utilizing l-DOPA is the gold standard symptomatic treatment for Parkinson's disease (PD). A critical complication of this therapy is the development of l-DOPA-induced dyskinesia (LID). The endogenous opioid peptides, including enkephalins and dynorphin, are co-transmitters of dopaminergic, GABAergic, and glutamatergic transmission in the direct and indirect striatal output pathways disrupted in PD, and alterations in expression levels of these peptides and their precursors have been implicated in LID genesis and expression. We have previously shown that the opioid glycopeptide drug MMP-2200 (a.k.a. Lactomorphin), a glycosylated derivative of Leu-enkephalin mediates potent behavioral effects in two rodent models of striatal DA depletion. In this study, the mixed mu-delta agonist MMP-2200 was investigated in standard preclinical rodent models of PD and of LID to evaluate its effects on abnormal involuntary movements (AIMs). MMP-2200 showed antiparkinsonian activity, while increasing l-DOPA-induced limb, axial, and oral (LAO) AIMs by ∼10%, and had no effect on dopamine receptor 1 (D1R)-induced LAO AIMs. In contrast, it markedly reduced dopamine receptor 2 (D2R)-like-induced LAO AIMs. The locomotor AIMs were reduced by MMP-2200 in all three conditions. The N-methyl-d-aspartate receptor (NMDAR) antagonist MK-801 has previously been shown to be anti-dyskinetic, but only at doses that induce parkinsonism. When MMP-2200 was co-administered with MK-801, MK-801-induced pro-parkinsonian activity was suppressed, while a robust anti-dyskinetic effect remained. In summary, the opioid glycopeptide MMP-2200 reduced AIMs induced by a D2R-like agonist, and MMP-2200 modified the effect of MK-801 to result in a potent reduction of l-DOPA-induced AIMs without induction of parkinsonism." @default.
• W2892329410 created "2018-09-27" @default.
• W2892329410 creator A5004674693 @default.
• W2892329410 creator A5041020554 @default.
• W2892329410 creator A5060086714 @default.
• W2892329410 creator A5068874736 @default.
• W2892329410 creator A5071744431 @default.
• W2892329410 creator A5078293143 @default.
• W2892329410 creator A5080124691 @default.
• W2892329410 creator A5091535892 @default.
• W2892329410 creator A5091654390 @default.
• W2892329410 date "2018-10-01" @default.
• W2892329410 modified "2023-10-17" @default.
• W2892329410 title "The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia" @default.
• W2892329410 cites W1565618785 @default.
• W2892329410 cites W1586476523 @default.
• W2892329410 cites W1587395327 @default.
• W2892329410 cites W1642086117 @default.
• W2892329410 cites W1838555322 @default.
• W2892329410 cites W1965138476 @default.
• W2892329410 cites W1968862955 @default.
• W2892329410 cites W1970167815 @default.
• W2892329410 cites W1970853027 @default.
• W2892329410 cites W1976108730 @default.
• W2892329410 cites W1987458904 @default.
• W2892329410 cites W1991603311 @default.
• W2892329410 cites W1993557467 @default.
• W2892329410 cites W1997274212 @default.
• W2892329410 cites W2011513589 @default.
• W2892329410 cites W2013091928 @default.
• W2892329410 cites W2014110722 @default.
• W2892329410 cites W2015083680 @default.
• W2892329410 cites W2019511637 @default.
• W2892329410 cites W2020333215 @default.
• W2892329410 cites W2025102930 @default.
• W2892329410 cites W2031740174 @default.
• W2892329410 cites W2032242033 @default.
• W2892329410 cites W2033662966 @default.
• W2892329410 cites W2034945701 @default.
• W2892329410 cites W2040774095 @default.
• W2892329410 cites W2045914012 @default.
• W2892329410 cites W2046319965 @default.
• W2892329410 cites W2047099152 @default.
• W2892329410 cites W2050129233 @default.
• W2892329410 cites W2051217412 @default.
• W2892329410 cites W2052631985 @default.
• W2892329410 cites W2065259691 @default.
• W2892329410 cites W2065434356 @default.
• W2892329410 cites W2069367875 @default.
• W2892329410 cites W2072572338 @default.
• W2892329410 cites W2073630554 @default.
• W2892329410 cites W2074616189 @default.
• W2892329410 cites W2077172541 @default.
• W2892329410 cites W2081509710 @default.
• W2892329410 cites W2089396553 @default.
• W2892329410 cites W2091212941 @default.
• W2892329410 cites W2092634694 @default.
• W2892329410 cites W2092896353 @default.
• W2892329410 cites W2106350754 @default.
• W2892329410 cites W2108264490 @default.
• W2892329410 cites W2109194925 @default.
• W2892329410 cites W2109593203 @default.
• W2892329410 cites W2110806949 @default.
• W2892329410 cites W2112391315 @default.
• W2892329410 cites W2113268577 @default.
• W2892329410 cites W2116939568 @default.
• W2892329410 cites W2119313744 @default.
• W2892329410 cites W2120653271 @default.
• W2892329410 cites W2140463558 @default.
• W2892329410 cites W2142453914 @default.
• W2892329410 cites W2149136827 @default.
• W2892329410 cites W2154011816 @default.
• W2892329410 cites W2168954492 @default.
• W2892329410 cites W2169756430 @default.
• W2892329410 cites W2173305081 @default.
• W2892329410 cites W2314410103 @default.
• W2892329410 cites W2322912881 @default.
• W2892329410 cites W2404415202 @default.
• W2892329410 cites W2811281088 @default.
• W2892329410 cites W3185454048 @default.
• W2892329410 cites W4230194219 @default.
• W2892329410 cites W4239908405 @default.
• W2892329410 cites W95961711 @default.
• W2892329410 doi "https://doi.org/10.1016/j.neuropharm.2018.09.005" @default.
• W2892329410 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6309213" @default.
• W2892329410 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30201210" @default.
• W2892329410 hasPublicationYear "2018" @default.
• W2892329410 type Work @default.
• W2892329410 sameAs 2892329410 @default.
• W2892329410 citedByCount "13" @default.
• W2892329410 countsByYear W28923294102019 @default.
• W2892329410 countsByYear W28923294102020 @default.
• W2892329410 countsByYear W28923294102022 @default.
• W2892329410 countsByYear W28923294102023 @default.
• W2892329410 crossrefType "journal-article" @default.
• W2892329410 hasAuthorship W2892329410A5004674693 @default.
• W2892329410 hasAuthorship W2892329410A5041020554 @default.
• W2892329410 hasAuthorship W2892329410A5060086714 @default.

• next